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data suggested a better comfort for the patient for linac-
based therapy, due to the shorter treatment time and the 
non-invasive immobilization system. Dosimetric data for the 
patients treated according to this protocol suggest a 
substantial balance between Gamma Knife and Linac EDGE 
treatments 
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Purpose or Objective: By pooling data of five large 
prospective studies/Institutional series, a large data base of 
pT2-pT3, pN0 patients treated either in the adjuvant or in 
the salvage setting with conventionally fractionated (1.8-2.0 
Gy/fr) 3DCRT post-prostatectomy radiotherapy (RT) was 
available. The aim of the study was to fit individual data of 
biochemical-recurrence-free survival (bRFS) with a 
comprehensive Poisson-based TCP model. 
 
Material and Methods: Considering pre-RT PSA as a surrogate 
of the number of clonogens, 5-year bRFS was expressed as a 
function of the dose depending on radiosensitivity (α_eff), 
number of clonogens for pre-RT PSA=1ng/mL (C) and the 
fraction of patients that relapses due to clonogens outside 
the treated volume, assumed to linearly depend on pre-RT 
PSA (K=1-BxPSA), according to:  
bRFS = (1-B x PSA) x [1 - exp (-α_eff D)]^CxPSA.  
In addition, the impact of Gleason score (GS) was included by 
performing separate fits for different sub-groups, depending 
on GS (<7,=7,>7). In total, complete data regarding bRFS, 
dose, pre-RT PSA (between 0.01 and 2.0 ng/ml) and GS of 
894 hormono-naive patients treated with adjuvant (n=331) or 
salvage (n=563) intent with a minimum follow-up of 3 years 
were available. Patients with GS<7, =7 and >7 were 392, 383, 
and 119 respectively. Best-fit procedures were performed 
with the sequential quadratic programming, using the sum of 
the squared residuals error as loss function (SPSS v.17, SPSS 
Inc., Chicago, IL). The 95% CI of the parameter’s best-fit 
values were calculated by bootstrap. The performance of the 
resulting model was assessed by calibration plot. 
 
Results: The median follow-up was 72 months; median pre-
RT PSA and dose were 0.25 ng/mL (inter-quartile range: 0.1-
0.5) and 66.6Gy (range:59.4-77.4Gy) respectively. The fit 
converged in all situations: depending on GS, best-fit values 
were in the range 0.20-0.22 Gy-1 and 10^6 for α_eff and C 
respectively; the maximum obtainable bRFS was reduced by 
1.7, 4.9 and 5.6% for each 0.1ng/ml PSA increment for GS<7, 
=7 and >7 respectively. The calibration plot showed an 
excellent agreement between predicted and expected values 
(R2=0.96) and the AUC was 0.69 (95% CI: 0.66-0.73). The 
bRFS curves as estimated by the model vs prescribed dose for 
different pre-RT PSA (between 0.1 and 1.0 ng/ml) and for the 
three GS groups are plotted in the figure. 
 
 
Conclusion: Long-term bRFS data of a large multi-centric 
data base of post-prostatectomy patients could be fitted by a 
radiobiologically consistent TCP model, showing a dose-effect 
critically depending on pre-RT PSA and GS. The model 
suggests that most relapses occur in patients with clonogens 
outside the treated volume, indirectly supporting lymph-
nodal irradiation and/or systemic therapy for specific risk 
groups, depending on pre-RT PSA and GS. Early RT is 
preferred over delayed RT as the detrimental effect due to a 
PSA increase can never be compensated by increasing the 
dose, more dramatically evident for patients with GS ≥7. 
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Purpose or Objective: Traditional normal tissue complication 
probability (NTCP) models rely on dose-volume histogram 
(DVH) analysis, which disregards any spatial dose distribution 
information and possible inhomogeneity in regional organ 
radio-sensitivity. We propose a voxel-based (VB) approach to 
correlate local lung dose and radiation-induced lung damage 
(RILD). 
 
Material and Methods: An inter-institutional database of 115 
Hodgkin lymphoma survivors treated with sequential chemo-
radiotherapy (with 18 RILD cases after treatment) were 
included in the study. Sixteen patients were excluded due to 
an inadequate CT coverage of the lungs. 
Each patient dataset was first normalized to a common 
template. Pre-registration steps were based on a binary mask 
extrapolated from the organ at risk segmentations of the 
treatment plan. For each patient, the mask, computed as the 
union and dilation (spherical structuring element of radius 30 
mm) of heart and lung structures, was used to crop the field-
of-view, allowing a coarse alignment of the structures of 
interest. CT images were masked accordingly in order to hide 
some anatomical inter-individual differences, and allowed 
the registration algorithm to work more efficiently on tissue 
contrast inside the chest. The median lung-volume patient 
was chosen as reference image in the non-rigid registration 
and a log-diffeomorphic approach [1] was used. The obtained 
deformation fields were then used to map the dose of each 
patient to the common coordinate system of the reference 
patient. 
A voxel-wise two-sample t-test was then performed on the 
normalized dose maps and statistically significance of the 
differences between groups was displayed as p-value map. 
 
Results: The robustness of co-registration process was 
assessed both by visual inspection (Fig. 1a-b) and by Dice 
scores for the lungs (Fig. 1c). On the whole population, the 
median Dice value was 0.94 (range: [0.87; 0.95]). As shown in 
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Fig. 1d-f, a significantly (p < 0.01) higher dose was delivered 
to RILD patients nearby the basal portion of the right lung 
and the submantellar region of the left lung. The average 
dose delivered to this volume (9.4% of the lungs) was of 5.3 
Gy in RILD patients and 2.6 Gy in non-RILD patients. 
 
 
 
Conclusion: By a VB approach we were able to highlight local 
dose-RILD relationship in the lungs. Interestingly, a 
significantly different dose was delivered in the low-dose (~ 5 
Gy) parenchymal regions, in agreement with previous DVH 
analyses showing that the volume exceeding 5 Gy is 
consistently more predictive than other dosimetric variables. 
In order to obtain more powerful insights on local lung 
radiosensitivity, this preliminary results should be enriched 
by applying the VB approach to larger databases evaluating 
RILF in heterogeneously treated lungs. 
[1] Vercauteren T, Pennec X, Perchant A, Ayache N. 
Symmetric log-domain Diffeomorphic registration: A demons-
based approach. In lecture notes in computer science: Vol 
5241. MICCAI 2008 
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Purpose or Objective: Particle therapy has the potential to 
improve radiotherapy due to the increase in dose conformity 
and RBE. The RBE depends on multiple factors including cell 
type, dose, particle type and energy. Accordingly, a variable 
RBE is clinically applied for carbon ion therapy, in contrast to 
a prescribed constant RBE = 1.1 in proton therapy 
jeopardizing part of its accuracy. Therefore, it is the aim to 
enhance proton therapy by translating a more realistic RBE 
description into the clinic directly based on clinical (and 
preclinical) experience gained with photons and heavier ions 
such as helium and carbon ions. 
 
Material and Methods: The RBE is considered to depend on a) 
the dose response of the biological endpoint and b) the 
heterogeneity of the dose distribution on the cellular level 
(similar to the local effect model). The heterogeneity is 
determined by the clinically accessible (prescribed) dose D 
and the beam quality Q = Z²/E (varying within the patient), 
where Z and E are the ion charge and kinetic energy, 
respectively. We propose an approach to obtain proton RBE 
by interpolating between the biological effectiveness of a 
homogeneous dose distribution for photons and an 
increasingly heterogeneous distribution for heavier and 
slower ions. Based on the linear-quadratic (LQ) model and 
the dose heterogeneity an analytical description of the 
radiobiological effect was derived. It suggests a linear 
increase of the LQ parameter for particle irradiation αP with 
beam quality Q. In vitro RBE data from the literature for 
different ion types, cell lines, and within clinically relevant 
LET ranges (below the RBE maximum) were analyzed. 
 
Results: The considered RBE data seem to depend directly on 
beam quality Q (Figure 1a). In contrast, particle type 
together with LET appear as a surrogate for beam quality Q 
(Figure 1b). In accordance with the derived description, the 
LQ parameter αP increases linearly with Q (Figure 1c) and the 
RBE (Figure 1d) as well as αP could be approximated for all 
considered ions and cell lines with a simple formula 
depending on Q, D, and the photon LQ parameters αX and βX. 
The deviations between prediction and experiment are 
mostly within 10 - 20% and therefore on the order of 
uncertainties often associated with RBE experiments. The 
variation of βP with Q was much weaker and less conclusive. 
 
 
 
Conclusion: As long as cells “experience” a comparable 
microscopic dose distribution they cannot distinguish 
between different ion beams confirming that RBE variability 
also exists in proton therapy. More realistic RBE values for 
proton therapy may be directly obtained from available 
empirical RBE data for heavier ions considering the same 
beam quality Q and endpoint or, alternatively, by 
interpolating between empirical data from photon irradiation 
and heavier ions. Experimental preclinical (and clinical) data 
should be gathered in order to validate the proposed strategy 
to enhance proton therapy. 
 
 
 
 
 
 
